Cildir Sule Kavaloglu, Sandalli Nuket, Nazli Serpil, Alp Fatos, Caglar Esber
Department of Pedodontics, Faculty of Dentistry, Yeditepe University, Istanbul, Turkey.
Cleft Palate Craniofac J. 2012 May;49(3):369-72. doi: 10.1597/10-035. Epub 2011 Feb 10.
The aim of the present study was to investigate the effect of the probiotic bacterium Lactobacillus reuteri on the levels of salivary mutans streptococci and lactobacilli in children with cleft lip/palate who used the novel drop containing L. reuteri.
The study group consisted of 19 operated cleft lip/palate children aged 4 to 12 years. The study had a double-blind, randomized crossover design, and the experimental period consisted of four consecutive time periods. During periods 2 and 4, consisting of 25 days each, parents were instructed that their children should consume 5 drops per day (0.15 to 0.20 g) of probiotic or placebo drops produced by the same manufacturer. The probiotic drop, BioGaia Reuteri drops, contained L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (≥1 × 10(8) CFU/5 drops). The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT tests. The data were processed with NCSS 2007 software using chi-square and McNemar tests.
There was no statistically significant (p > .05) reduction of salivary mutans streptococci and lactobacilli after 25 days of consumption of both drops.
The novel drop containing L. reuteri may not reduce the levels of salivary mutans streptococci and lactobacilli in cleft lip/palate children.
本研究旨在调查益生菌罗伊氏乳杆菌对唇腭裂患儿唾液变形链球菌和乳酸菌水平的影响，这些患儿使用了含罗伊氏乳杆菌的新型滴剂。
研究组由19名4至12岁接受唇腭裂手术的儿童组成。该研究采用双盲、随机交叉设计，实验期包括四个连续时间段。在各为期25天的第2和第4时间段，指导家长让孩子每天服用5滴（0.15至0.20克）同一厂家生产的益生菌滴剂或安慰剂滴剂。益生菌滴剂BioGaia Reuteri滴剂含有罗伊氏乳杆菌DSM 17938和罗伊氏乳杆菌ATCC PTA 5289（≥1×10⁸CFU/5滴）。使用CRT试验评估唾液变形链球菌和乳酸菌的计数。数据用NCSS 2007软件进行卡方检验和McNemar检验处理。
服用两种滴剂25天后，唾液变形链球菌和乳酸菌数量均无统计学显著减少（p>.05）。
含罗伊氏乳杆菌的新型滴剂可能不会降低唇腭裂患儿唾液变形链球菌和乳酸菌的水平。
